New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:14 EDTGHDXGenomic Health's Oncotype DX for prostate cancer shows positive results
Genomic Health announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research demonstrating that the Oncotype DX Genomic Prostate Score predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a predictor of biochemical recurrence, a rise in prostate-specific antigen following surgery, which is a measure of longer-term outcomes for aggressive disease. Additional endpoints of this prostate cancer study include the development of metastatic disease and outcomes in African-American patients.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 20, 2015
08:04 EDTGHDXGenomic Health reports positive data on positive impact of Oncotype DX test
Genomic Health announced that 11 studies were presented at the 14th St. Gallen International Breast Cancer Conference, including positive results from a real-life observational study in Ireland.1 That study demonstrated that use of the Oncotype DX test in early-stage breast cancer led to a 58 percent net reduction in chemotherapy use, resulting in net cost savings of nearly EUR 800,000, or approximately EUR 1,200 in cost savings per patient.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use